2026 Scrip Asia 100
Latest Updates And Considerations In Asia Pacific
India’s rise, Japan’s innovation, and Korea’s struggles show how Asia is reshaping the clinical trial landscape. Regional strengths and setbacks are redefining global research.
Japan has emerged as a global leader in the development of new drugs for the rare cancer angiosarcoma, reflecting its rapidly ageing population and the limitations of current therapies.
DIA Korea hears how multiple domestic and global factors are affecting the environment for clinical trials in South Korea, and what actions may be taken to address this.
Akeso’s penpulimab will be the second to hit the US market for nasopharyngeal carcinoma, but the first to win FDA approval for the indication based on clinical findings in US patients.
